Midatech Pharma plc logo
Midatech Pharma plc MTP

Quarterly report 2025-Q4
added 05-14-2026

report update icon

Midatech Pharma plc Cost of Revenue 2011-2026 | MTP

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Midatech Pharma plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - - 926 K 667 K 70 K - - - -

All numbers in GBP currency

Indicator range from annual reports

Maximum Minimum Average
926 K 70 K 554 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
62.5 K - 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
BioNTech SE BioNTech SE
BNTX
642 M $ 92.25 0.12 % $ 22.3 B germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
10.6 B - - $ 96.9 B britainBritain
Compugen Ltd. Compugen Ltd.
CGEN
9.25 M $ 2.65 -5.36 % $ 248 M israelIsrael
Abcam plc Abcam plc
ABCM
91.2 M - - $ 4.9 B britainBritain
Celyad Oncology SA Celyad Oncology SA
CYAD
515 K - - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
24.8 M - -7.31 % $ 87 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
602 K - - $ 7.46 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
13.8 M $ 1.64 1.86 % $ 192 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
49 M $ 14.89 0.07 % $ 214 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.85 M - 5.93 % $ 314 M canadaCanada
CureVac N.V. CureVac N.V.
CVAC
238 M - - $ 867 M germanyGermany
AIkido Pharma AIkido Pharma
AIKI
145 M - 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
1.36 M - -0.23 % $ 916 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
36.7 M $ 21.11 1.2 % $ 2.69 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
244 K - -11.43 % $ 502 K usaUSA